ブライトパス・バイオ(株)
株価チャート
2026/08/24 更新株価トレンド
2026/08/24 更新株価・取引詳細
2026/08/24 更新株価
取引
株主構成
2026/08/01 更新財務パフォーマンス
2026/08/23 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥0億 | ¥0億 | ¥0億 | ¥0億 |
| 売上総利益 | ¥0億 | ¥0億 | ¥0億 | ¥0億 |
| 営業利益 | -¥15億 | -¥12億 | -¥12億 | -¥13億 |
| 経常利益 | -¥15億 | -¥12億 | -¥12億 | -¥13億 |
| 当期純利益 | -¥15億 | -¥12億 | -¥12億 | -¥13億 |
| EPS | -¥24.90 | -¥18.21 | -¥14.12 | -¥11.70 |
| 営業利益率 | -27,785.21% | -1,604,276.39% | -102,464.08% | -1,541,667.86% |
| 貸借対照表 | ||||
| 総資産 | ¥17億 | ¥12億 | ¥11億 | ¥26億 |
| 純資産 | ¥16億 | ¥10億 | ¥9億 | ¥24億 |
| 総負債 | ¥1億 | ¥3億 | ¥2億 | ¥2億 |
| 現金 | ¥15億 | ¥11億 | ¥8億 | ¥22億 |
| 有利子負債 | ¥0億 | ¥1億 | ¥0億 | ¥0億 |
| 自己資本比率 | 92.13% | 79.58% | 82.54% | 90.92% |
| D/Eレシオ | 0.00 | 0.11 | 0.03 | 0.00 |
| キャッシュフロー | ||||
| 営業CF | -¥12億 | -¥12億 | -¥13億 | -¥14億 |
| 投資CF | -¥0億 | -¥0億 | -¥0億 | -¥0億 |
| 財務CF | ¥4億 | ¥7億 | ¥10億 | ¥27億 |
| フリーCF | -¥12億 | -¥12億 | -¥13億 | -¥14億 |
| 効率性 | ||||
| ROE | -94.77% | -119.32% | -124.45% | -55.10% |
| ROA | -87.32% | -94.95% | -102.73% | -50.10% |
最新IR情報
最新ニュース (5件)
企業情報
会社概要
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.
